Subject(s)
Antibodies, Viral/biosynthesis , BNT162 Vaccine/immunology , COVID-19/prevention & control , Immunoglobulin G/biosynthesis , Immunotherapy, Adoptive , SARS-CoV-2/immunology , Adult , Aged , Antigens, Viral/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , BNT162 Vaccine/adverse effects , Biological Products/therapeutic use , Combined Modality Therapy , Female , Fever/etiology , Hematopoietic Stem Cell Transplantation , Humans , Immunization, Secondary , Immunocompromised Host , Immunogenicity, Vaccine , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Pain/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Receptors, Antigen, T-Cell/therapeutic use , Receptors, Chimeric Antigen/therapeutic use , Spike Glycoprotein, Coronavirus/immunology , Vaccination , Young AdultABSTRACT
This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 109/L) and immunosuppressive treatment or chemotherapy at the time of vaccination.